Rational design and engineering of a modified adeno-associated virus (AAV1)-Based vector system for enhanced retrograde gene delivery

Neurosurgery

Volumn 76, Issue 2, 2015, Pages 216-225

  Davis, Adam S ^a   Federici, Thais ^b   Ray, William C ^a,c   Boulis, Nicholas M ^a   O'Connor, Deirdre ^a   Reed Clark, K ^a,c,d   Bartlett, Jeffrey S ^e  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Immunology and Medical Genetics   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Calimmune Australia Inc   (United States)

Author keywords

AAV mediated gene delivery; Motor neuron disease; Rational design; Retrograde axonal transport; Vector engineering; Vector targeting

Indexed keywords

CAPSID PROTEIN; EPITOPE; PARVOVIRUS VECTOR; TET1 PEPTIDE; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; TET1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOSAICISM; MOTONEURON; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; RAT; RETROGRADE NERVE FIBER TRANSPORT; SPINAL CORD NERVE CELL; TROPISM; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS RECOMBINANT; ANIMAL; CHEMISTRY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEK293 CELL LINE; HELA CELL LINE; PROCEDURES; PROTEIN QUATERNARY STRUCTURE; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; CAPSID PROTEINS; DEPENDOVIRUS; DNA-BINDING PROTEINS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HELA CELLS; HUMANS; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TRANSDUCTION, GENETIC;

EID: 84925941067     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/NEU.0000000000000589     Document Type: Article

References (39)

1. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-1172.
2. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004;10(2):302-317.
3. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301(5634):839-842.
4. Liu JK, Teng Q, Garrity-Moses M, et al. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol Dis. 2005; 19(3):407-418.
5. Federici T, Liu JK, Teng Q, Yang J, Boulis NM. A means for targeting therapeutics to peripheral nervous system neurons with axonal damage. Neurosurgery. 2007;60(5):911-918; discussion 911-918.
6. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology. 1999;265(2):274-285.
7. Girod A, Ried M, Wobus C, et al. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nat Med. 1999;5(12):1438.
8. Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther. 2001;3(6):964-975.
9. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol. 2000;74(18):8635-8647.
10. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther. 2001;12(14):1697-1711.
11. Shi W, Bartlett JS. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther. 2003;7(4):515-525.
12. Shi W, Hemminki A, Bartlett JS. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2- mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol. 2006;103(3):1054-1062.
13. Stachler MD, Bartlett JS. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 2006;13(11):926-931.
14. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002;76(2):791-801.
15. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72(3):2224-2232.
16. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6(6):973-985.
17. Okada T, Nonaka-Sarukawa M, Uchibori R, et al. Scalable purification of adenoassociated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum Gene Ther. 2009;20(9):1013-1021.
18. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36(1):59-74.
19. Clark KR, Voulgaropoulou F, Johnson PR. A stable cell line carrying adenovirusinducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther. 1996;3(12):1124-1132.
20. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature. 1977;270(5639):725-727.
21. Vincent AM, Feldman EL, Song DK, et al. Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro. Neuromolecular Med. 2004;6(2-3):79-85.
22. Campenot RB. Development of sympathetic neurons in compartmentalized cultures, II: local control of neurite survival by nerve growth factor. Dev Biol. 1982;93(1):13-21.
23. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22(2):195-201.
24. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 2009;37(database issue):D387-D392.
25. Wu S, Skolnick J, Zhang Y. Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol. 2007;5:17.
26. Zhang Y. Template-based modeling and free modeling by I-TASSER in CASP7. Proteins. 2007;69(suppl 8):108-117.
27. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9:40.
28. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781-1802.
29. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 2006;14(1):97-106.
30. Clark KR, Liu X, McGrath JP, Johnson PR. Highly purified recombinant adenoassociated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther. 1999;10(6):1031-1039.
31. Hollis ER II, Kadoya K, Hirsch M, Samulski RJ, Tuszynski MH. Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther. 2008;16(2):296-301.
32. Hellinga HW. Computational protein engineering. Nat Struct Biol. 1998;5(7):525-527.
33. Wilks HM, Holbrook JJ. Alteration of enzyme specificity and catalysis by protein engineering. Curr Opin Biotechnol. 1991;2(4):561-567.
34. Arnold FH, Haymore BL. Engineered metal-binding proteins: purification to protein folding. Science. 1991;252(5014):1796-1797.
35. Higaki JN, Haymore BL, Chen S, Fletterick RJ, Craik CS. Regulation of serine protease activity by an engineered metal switch. Biochemistry. 1990;29(37):8582-8586.
36. Browner MF, Hackos D, Fletterick R. Identification of the molecular trigger for allosteric activation in glycogen phosphorylase. Nat Struct Biol. 1994;1(5):327-333.
37. Brinen LS, WillettWS, CraikCS, Fletterick RJ. X-ray structures of a designed binding site in trypsin show metal-dependent geometry. Biochemistry. 1996;35(19):5999-6009.
38. Bryson JW, Betz SF, Lu HS, et al. Protein design: a hierarchic approach. Science. 1995;270(5238):935-941.
39. Towne C, Schneider BL, Kieran D, Redmond DE Jr, Aebischer P. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther. 2010;17(1):141-146.